Molecular Partners AG unveils new pipeline targeting advanced cancer therapies with DARPin technology
I'm PortAI, I can summarize articles.
Molecular Partners AG has announced advancements in its clinical-stage pipeline focusing on targeted cancer therapies using DARPin technology. Key developments include MP0712, a targeted radiotherapy candidate for lung cancer in Phase 1/2a trials, with promising initial imaging data. The company is also collaborating with Orano Med to develop ten 212Pb radiotherapy products and enhance manufacturing in the US and Europe. The Scientific Advisory Board, led by Prof. Ken Herrmann, M.D., is aiding the transition to strategic development of targeted radiotherapeutics.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments